| 분자 | Cat. No. | Product Name | 종 | Host | 구조 | 순도 | Activity | 규격 및 가격 |
|---|---|---|---|---|---|---|---|---|
| IL-4 | HOT IL4-H5253 | Human IL-4 Protein, Fc Tag, low endotoxin (MALS verified) | Human | HEK293 | ![]() | MALSSDS-PAGE | $415.00 100ug | |
| IL-4 | HOT IL4-H52H9 | Human IL-4 Protein, His Tag, low endotoxin (Mass Spec & MALS verified) | Human | HEK293 | ![]() | MALSSDS-PAGE | $415.00 100ug | |
| IL-4 | HOT IL4-H4218 | Human IL-4 Protein, premium grade | Human | HEK293 | ![]() | HPLCSDS-PAGE | $215.00 20ug | |
| IL-4 | HOTAvitag IL4-H82E0 | Biotinylated Human IL-4 Protein, Avitag™,His Tag (MALS verified) | Human | HEK293 | ![]() | MALSSDS-PAGE | $415.00 25ug | |
| IL-4 | HOT GMP-L04H26 | GMP Human IL-4 Protein | Human | HEK293 | ![]() | SDS-PAGE | $830.00 50ug | |
| IL-4 | Cynomolgus IL-4 Protein, Fc Tag (MALS verified) | Cynomolgus | HEK293 | ![]() | MALSSDS-PAGE | $395.00 100ug | ||
| IL-4 | Cynomolgus IL-4 Protein, His Tag (MALS verified) | Cynomolgus | HEK293 | ![]() | MALSSDS-PAGE | $360.00 100ug | ||
| IL-4 | Avitag IL4-C82E3 | Biotinylated Cynomolgus IL-4 Protein, His,Avitag™ (MALS verified) | Cynomolgus | HEK293 | ![]() | MALSSDS-PAGE | $360.00 25ug | |
| IL-4 | Human IL-4 Protein, Research Grade | Human | HEK293 | ![]() | HPLCSDS-PAGE | $189.00 20ug | ||
| IL-4 | Mouse IL-4 Protein, His Tag | Mouse | HEK293 | ![]() | SDS-PAGE | $395.00 100ug |
| 영어 이름 | 연구 코드 | 연구 개발 단계 | 회사 | 적응증 | 임상 시험 |
|---|---|---|---|---|---|
| Dupilumab biosimilar (Jingxing Pharmaceutical) | GS101; GS-101; GS-101 (Jingxing Pharmaceutical) | Phase 3 Clinical | Jiangsu Jingxing Pharmaceutical Technology Co Ltd | Dermatitis, Atopic | 상세 |
| Dupilumab biosimilar (Qilu Pharma) | QL2108; QL-2108 | Phase 3 Clinical | Qilu Pharmaceutical Co Ltd | Asthma; Dermatitis, Atopic; Prurigo | 상세 |
| Tilrekimig | PF-07275315 | Phase 3 Clinical | Pfizer Inc | Asthma; Dermatitis, Atopic; Pulmonary Disease, Chronic Obstructive | 상세 |
| Eblasakimab | MK-6105; ASLAN-004; CSL-334 | Phase 2 Clinical | Csl Ltd, Merck Sharp & Dohme Corp | Dermatitis, Atopic; Hypersensitivity | 상세 |
| Dectrekumab/VAK-694 | QBX-258 | Phase 2 Clinical | Novartis Pharma Ag | Asthma; Lymphedema | 상세 |
| OCH-NCNP1 | OCH-NCNP1 | Phase 2 Clinical | Keio University | Crohn Disease; Multiple Sclerosis | 상세 |
| Ompekimig | PF-07264660 | Phase 2 Clinical | Pfizer Inc | Dermatitis, Atopic | 상세 |
| AUP1602-C | AUP-16; AUP1602-C | Phase 2 Clinical | Aurealis | Diabetic Foot; Ulcer | 상세 |
| Dupixent biosimilar (Chong Kun Dang Pharmaceutical) | CKD-706 | Phase 1 Clinical | Chong Kun Dang Pharmaceutical Corp | Dermatitis, Atopic | 상세 |
| Dupilumab biosimilar (China Resources Biopharma) | Phase 1 Clinical | China Resources Biopharmaceutical Co Ltd | Dermatitis, Atopic | 상세 | |
| Dupilumab biosimilar (Jiangsu Jingxing Pharma) | Phase 1 Clinical | Jiangsu Jingxing Pharmaceutical Technology Co Ltd | Dermatitis, Atopic | 상세 | |
| Dupilumab biosimilar (Chengdu Kanghong) | KH-816; KH816 | Phase 1 Clinical | Chengdu Kanghong Biotechnologies Co Ltd | Dermatitis, Atopic | 상세 |
| Dupilumab biosimilar (Jushi Biopharma) | Phase 1 Clinical | Jushi Biopharmaceutical Co Ltd | Dermatitis, Atopic | 상세 | |
| Dupilumab biosimilar (Bio-Thera Solutions) | BAT2406; BAT-2406 | Phase 1 Clinical | Bio-Thera Solutions Ltd | Asthma; Dermatitis, Atopic; Eosinophilic Esophagitis; Nasal Polyps; Prurigo Nodularis; Sinusitis | 상세 |
| 영어 이름 | 연구 코드 | 연구 개발 단계 | 회사 | 가장 빠른 브랜드 이름 | 가장 빠른 승인 국가 | 가장 빠른 적응증 | 가장 빠른 승인 회사 | 가장 빠른 승인 날짜 | 적응증 | 임상 시험 |
|---|---|---|---|---|---|---|---|---|---|---|
| Dupilumab | REGN-668; SAR-231893 | Approved | Regeneron Pharmaceuticals Inc, Sanofi | Dupixent, 达必妥 | United States | Dermatitis, Atopic | Regeneron Pharmaceuticals Inc | 2017-03-28 | Allergic Fungal Rhinosinusitis; Alopecia Areata; Angioedema; Aspergillosis, Allergic Bronchopulmonary; Asthma; Asthma, Aspirin-Induced; Chronic Urticaria; Colitis, Ulcerative; Conjunctivitis, Allergic; Coronavirus Disease 2019 (COVID-19); Dermatitis; Dermatitis, Atopic; Eczema; Eosinophilic Esophagitis; Eosinophilic gastroenteritis (EG); Genetic Diseases, Inborn; Hypereosinophilic Syndrome; Hypersensitivity; Hypersensitivity, Immediate; Keloid; Keratoconjunctivitis; Lichenoid Eruptions; Milk Hypersensitivity; Nasal Polyps; Nephrotic Syndrome; Neurodermatitis; Paranasal Sinus Diseases; Peanut Hypersensitivity; Pemphigoid, Bullous; Prostatic Neoplasms; Prurigo; Prurigo Nodularis; Pruritus; Pulmonary Disease, Chronic Obstructive; Respiration Disorders; Respiratory Sounds; Respiratory Tract Diseases; Rhinitis, Allergic; Scleroderma, Localized; Sinusitis; Skin Diseases; Skin Diseases, Eczematous; Sleep Apnea Syndromes; Urticaria | 상세 |
| Berdazimer sodium | NVN-1000-SB-206-Novan; SB-206; MAP3-NONOate - SB-206; NVN1000-SB206; SB-019; NI-MC101; SB-207; SB-208; SB-204; SB-414 | Approved | University Of North Carolina At Chapel Hill | KINSOLUSTM, Zelsuvmi, ZELSUVMI | United States | Molluscum Contagiosum | Lnhc Inc | 2024-01-05 | Acne Vulgaris; Condylomata Acuminata; Dermatitis, Atopic; Molluscum Contagiosum; Psoriasis; Tinea Pedis | 상세 |
